Promo piece on Tempus and Personalised Cancer Treatment.
According to the article published on Eric Lefkofsky's website, about a decade and a half ago, scientists first outlined the human genome and led many to believe that it would lead in a new era of customized therapies to treat cancer as well as many other diseases that affect humans. However, despite huge advances in technology and the knowledge people have about cancer, these group of diseases affects more than 600,000 people every year in the United States.
Even as the whole genome sequencing (WGS) has become cheaper and more widely available, patients with cancer are still treated the same way as they were a quarter-century ago. The United States health system hasn't yet found an effective and well-organized way to collect large results of molecular data, then combine it with an individual therapeutic data of a patient and analyze everything in a clinical setting and drive individual treatment decisions. The reason is that large data doesn't exist in the cancer field.
The two large sets of combined public data include only data not more than 20,000 patients, a small fraction of millions of people living with cancer all over the world. Cancer centers, hospitals, and even wide hospital networks do not have the resources required to sequence enough patients with cancer in a cost-effective way to aggregate molecular data, neither do they have technology resources or capital necessary for investing in analytics. Also, even the largest hospitals often see a small number of cancer patients, hence producing the volume of data required to get clinically important patterns would take time.
That is why Lefkofsky co-founded Tempus, a health technology company committed to bringing technology and large data together to better cancer care as well as provide physicians with the tools they need to customize treatments for their patients.
Tempus has recruited an elite team of accomplished software engineers, data scientists, computational biologists, as well as geneticists, who have developed analytic tools and software that work within an existing infrastructure of a hospital to analyze data as well as providing decision support for healthcare professionals whose patients aren't responding to conventional treatments.
The traction the company has gained within a short time of operation is proof that major hospital systems realize the need for the services Tempus is providing. The company announced a partnership with the Lurie Cancer Center and promised that there is more to come.
Tempus goal is for all patients to gain from the treatment of others that came before by offering doctors with a technology platform that gets experience as they forge more partnerships as well as gather more data. Tempus believes that it's the right time to provide healthcare providers with the tools they require to personalize cancer treatment.
About Eric Lefkofsky
He's the co-founder as well as the chief executive officer of Tempus. Lefkofsky is the co-founder as well as the chairman of Groupon, which is a global e-commerce marketplace. He's a founding partner of the Lightbank, a venture fund that invests in disruptive technology businesses.
Lefkofsky is also the co-founder of the following companies:
• Uptake Technologies, which is a predictive analytics platform for the largest industries in the world.
• InnerWorkings, a global managed print provider, and promotional solutions.
• Echo Global Logistics, which is a technology-enabled transportation as well as logistics outsourcing firm.
• Mediaocean, a company that provides integrated media procurement technology.
Your guide to living whole and well. Emma Olliff is a Registered Nutritional Therapist, wellness expert, food lover, and advocate for healthy living!